Richard Yeh

Richard Yeh currently works at Immvira Bioscience, Inc., as Independent Non-Executive Director from 2025, ADICON Holdings Ltd., as Independent Non-Executive Director from 2021, Medlive Technology Co., Ltd., as Independent Non-Executive Director from 2021, and Tasly Pharmaceutical Group Co., Ltd., as Director from 2024.
Mr. Yeh also formerly worked at Abbisko Therapeutics Co., Ltd., as CFO, Director & Head-Strategic Operations from 2021 to 2022, I-Mab, as Director, Chief Operating & Financial Officer from 2022 to 2024, Abbisko Cayman Ltd., as CFO, Executive Director & Head-Operations from 2020 to 2022, I-MAB Biopharma Co., Ltd., as Director, Amgen, Inc., as Research Associate, Citigroup Global Markets, Inc. (Broker), as Research Analyst, Canaccord Adams, Inc., as Research Associate from 2003 to 2004, GenoSpectra, Inc., as Corporate Development Manager, Wyeth Pharmaceuticals LLC, as Analyst, Needham & Co. LLC, as Research Analyst from 2005 to 2007, Citigroup Global Markets Asia Ltd., as Head of China Healthcare Research, Goldman Sachs (Asia) LLC, as Analyst, and CStone Pharmaceuticals Co. Ltd., as Chief Financial Officer from 2018 to 2020.
Mr. Yeh received his Masters Business Admin degree in 2002 from Cornell University, graduate degree in 1995 from the University of Toronto, and undergraduate degree in 1993 from the University of Manitoba.